Broken String Biosciences strengthens senior leadership team to accelerate product development and commercialization
Appointment of Vincent Smith, PhD, as Chief Technology Officer and Jessica Rich as VP Business Development
Follows Broken String’s successful $15M Series A fundraising round in September 20231
Will support development and commercialization strategy for INDUCE-seq DNA break-mapping platform
Cambridge, UK, 02 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are…
2 October 2023 - LifeArc, the self-funded, not-for-profit medical research organisation today announced the appointment of Stéphane Maikovsky as Interim Chief Executive Officer (CEO), succeeding Dr Melanie Lee who stepped down from the role last month.
Stéphane joined LifeArc as Chief Financial Officer (CFO) and Trustee in June 2022 to lead the organisation’s Finance, Investment, Early Ventures, Information Technology and Operational Effectiveness teams.
On taking up his new role, Stéphane said, "I am delighted to be leading this organisation to deliver our bold strategy, which will…
Global specialist in temperature-controlled logistics for life sciences, Biocair, has been awarded a 2023 EcoVadis silver medal for its overall achievements in sustainability. This is the second year that Biocair has achieved the silver medal from the esteemed sustainability rating provider.
EcoVadis is the leading provider of trusted business sustainability ratings with a global network of more than 100,000 rated companies. The EcoVadis methodology is based on international sustainability standards, like those from United Nations Global Impact (UNGC) and International Organization for…
Read the October eNews #lifescience newsletter here featuring:
✅ Welcome from Tony Jones, CEO
✅ Making the Most of Your Marketing Budget Through Engagement
✅ Understanding What You are Signing Up To in Life Science Contracts
✅ Transforming Employee Engagement Through Effective Communication
✅ Unveiling New Horizons in Paediatric Medicine Through Engagement
External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology, in preparation for customer use and commercialization
Cambridge, UK, 04 October 2023– EVONETIX LTD (‘Evonetix’), the Company developing semiconductor scale technology to improve access to gene synthesis, today announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London. This is the Company’s first platform to be installed in an external scientific setting; a significant milestone as it continues to optimize its gene synthesis…
Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy
Cambridge, UK, 4th October 2023: Mursla Bio is set to participate in the International Society of Extracellular Vesicle (ISEV) workshop to discuss optimal ways to translate EV-based biomarkers into clinical practice. This will include a focus on the regulatory requirements and commercial aspects. The workshop will feature the participation of The European Liquid Biopsy Society (ELBS).
Extracellular Vesicles (EVs), which contain multi-omics…
Alveron Pharma has successfully completed its first-in-human trial of OKL-1111, a new drug for the rapid treatment of intracranial haemorrhage associated with the use of anticoagulants or platelet inhibitors. The study was conducted at Hammersmith Medicines Research in London. OKL-1111 was well-tolerated in the trial with healthy human volunteers and showed no more adverse events above those in the placebo groups. Volunteers also received an anticoagulant and a pharmacodynamic effect was observed with OKL-1111 administration. In the prior non-clinical program, the drug reduced bleeding in a…
Press release
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).
Macomics’ operations are located in Edinburgh and…
Cambridge, UK – 27 September 2023 – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.
Together with this…
Reflects evolution of the Company from research and development towards scale-up and commercialization
Cambridge, UK, 26 September 2023– EVONETIX LTD (‘Evonetix’), the Company developing semiconductor scale technology to improve access to gene synthesis, today announces the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialization of its benchtop semiconductor gene synthesis platform. The rebrand follows a period of significant milestones, including external evaluation of Evonetix’s chip-synthesized DNA.
Evonetix’s gene…